SHINE-Vax Smart Hydrogel Microneedle Patches for mRNA Nanoparticle Vaccination
- Coordinator
- Karolinska Institutet, Sweden
- Runs
- 1 September 2027 to 31 August 2029
- Status
- Running
- EU funding
- €236k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101274031
What the project is doing
In the project's own words, from its summary on CORDIS.
The COVID-19 pandemic highlighted the transformative potential of mRNA vaccines, yet their delivery remains confined to intramuscular injections, which cause discomfort, reduce compliance, and rely on cold-chain logistics. Microneedle patches offer a minimally invasive alternative, but current systems mainly provide single-burst, fixed-dose release, limiting safety and efficacy. This project, SHINE-Vax, develops a temperature-responsive hydrogel microneedle system for controlled mRNA vaccine delivery.
Dual hydrogel layers with distinct phase transitions enable an initial release pulse at normal body temperature (~37 °C), sustained low-dose diffusion to reinforce immunity, and reversible suppression under fever-like conditions (~39 °C). Encapsulated lipid/polymer nanoparticles preserve mRNA integrity and stability, reducing cold-chain dependence. By integrating materials engineering, nanotechnology, and vaccine science, SHINE-Vax will deliver a proof-of-concept prototype (TRL 2–3) demonstrating autonomous, adaptive release.
This innovation aims to enhance vaccine efficacy and safety while broadening accessibility, particularly in resource-limited settings, positioning Europe at the forefront of next-generation, patient-friendly vaccination technologies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Karolinska Institutet | Stockholm | Sweden | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI